Last reviewed · How we verify

GB-0998 — Competitive Intelligence Brief

GB-0998 (GB-0998) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant C1-inhibitor replacement therapy. Area: Immunology / Rare Disease.

phase 3 Recombinant C1-inhibitor replacement therapy C1-inhibitor (C1-INH) Immunology / Rare Disease Small molecule Live · refreshed every 30 min

Target snapshot

GB-0998 (GB-0998) — Japan Blood Products Organization. GB-0998 is a recombinant human C1-inhibitor that regulates complement and contact system activation to prevent hereditary angioedema attacks.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
GB-0998 TARGET GB-0998 Japan Blood Products Organization phase 3 Recombinant C1-inhibitor replacement therapy C1-inhibitor (C1-INH)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant C1-inhibitor replacement therapy class)

  1. Japan Blood Products Organization · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GB-0998 — Competitive Intelligence Brief. https://druglandscape.com/ci/gb-0998. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: